TAG:
specialty lab
Specialty Laboratories, Enterix, Medicare, Blue Cross/Blue Shield Association
By Robert Michel | From the Volume X No. 15 – November 10, 2003 Issue
SPECIALTY LABORATORIES REPORTS THIRD QUARTER FINANCIAL PERFORMANCE THIRD QUARTER FINANCIAL REPORTS for Specialty Laboratories, Inc. show that the company is returning to a more normal routine, following the two unusual and unrelated events which hit it during 2002. Special…
Lab Acquisitions in 2002 Changed National Market
By Robert Michel | From the Volume X No. 8 – June 16, 2003 Issue
NEVER IN THE PAST THREE DECADES has there been so few laboratory companies—public and private—competing to offer lab testing services to office-based physicians. At the end of 2002, THE DARK REPORT’S annual ranking of public laboratory companies showed just 11 firms. Of these, two (Uni…
Specialty Laboratories, IMPATH, Roche, Abbott Laboratories, Celera Diagnostics
By Robert Michel | From the Volume X No. 6 – May 5, 2003 Issue
SPECIALTY LABORATORIES RESTORING STABILITY IN SPECIMEN VOLUME IT’S NO SURPRISE THAT COMPETITORS of Specialty Laboratories, Inc. have been willing to spread a variety of rumors about the laboratory company, given its well-publicized troubles with government regulators last …
“May 5, 2003 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume X No. 6 – May 5, 2003 Issue
There are rumors coming from the West Coast that government laboratory regulators are targeting at least one laboratory company for some significant violations. Because allegations of compliance violations by the government can severely damage a lab company’s reputation, there is a tight lid on infor…
Bio-Reference Labs, Quest Diagnostics, TriPath Imaging, Specialty Labs, SARS
By Robert Michel | From the Volume X No. 4 – March 24, 2003 Issue
BIO-REFERENCE LABS POSTS 20% INCREASE IN ANNUAL NET REVENUE LAST YEAR’S FRENZY of laboratory acquisitions left Bio-Reference Laboratories, Inc. of Elmwood Park, New Jersey as the nation’s third-largest public laboratory company focused primarily on physicians’ office t…
Lab Director Takes a Stand On Patented Genetic Testing
By Robert Michel | From the Volume X No. 3 – March 3, 2003 Issue
THIS LETTER APPEARED in the mailbag after our special intelligence briefing on how genetics will transform healthcare and before our look at how high-priced specialty esoteric testing is causing budget headaches for regional labs. (See TDRs, December 30, 2002 and …
New Market Channel For Esoteric Testing
By Robert Michel | From the Volume X No. 1 – January 20, 2003 Issue
CEO SUMMARY: It’s a new marketing model for specialty esoteric tests that presents both clinical and financial challenges to hospital and health system laboratories. Niche labs offering esoteric tests are sending sales reps directly to physicians and bypassing pathologists and lab direc…
Several Major Surprises Mark Events of 2002
By Robert Michel | From the Volume IX No. 17 – December 9, 2002 Issue
CEO SUMMARY: It was a year when the two blood brothers got much bigger and expanded market share by buying their largest competitors. With patient safety as the goal, employers began active steps to force hospitals, physicians, and other healthcare providers to use quality management syst…
HCA, Tenet , Specialty Labs
By Robert Michel | From the Volume IX No. 15 – October 28, 2002 Issue
HCA WANTS TO BUY HEALTH MIDWEST FOR $1.25 BILLION FOR-PROFIT HOSPITAL BEHEMOTH HCA Inc. announced an agreement in principal to acquire Health Midwest, a 14-hospital system based in Kansas City, Missouri. Subject to further negotiations and due diligence, H…
ARUP & Mayo Respond To New Market Cycle
By Robert Michel | From the Volume IX No. 14 – October 7, 2002 Issue
CEO SUMMARY: Since the beginning of 2002, several important events changed the competitive status quo among the nation’s leading providers of hospital send-out testing. As part of its ongoing assessment of this market segment, THE DARK REPORT provides strategic management insights from …
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized